PLGA-Curcumin.pdf (1.81 MB)
PLGA-Curcumin Attenuates Opioid-Induced Hyperalgesia and Inhibits Spinal CaMKIIα.
journal contributionposted on 2016-08-08, 00:00 authored by X Hu, F Huang, M Szymusiak, X Tian, Y Liu, ZJ Wang
Opioid-induced hyperalgesia (OIH) is one of the major problems associated with prolonged use of opioids for the treatment of chronic pain. Effective treatment for OIH is lacking. In this study, we examined the efficacy and preliminary mechanism of curcumin in attenuating OIH. We employed a newly developed PLGA-curcumin nanoformulation (PLGA-curcumin) in order to improve the solubility of curcumin, which has been a major obstacle in properly characterizing curcumin's mechanism of action and efficacy. We found that curcumin administered intrathecally or orally significantly attenuated hyperalgesia in mice with morphine-induced OIH. Furthermore, we demonstrated that the effects of curcumin on OIH correlated with the suppression of chronic morphine-induced CaMKIIα activation in the superficial laminae of the spinal dorsal horn. These data suggest that PLGA-curcumin may reverse OIH possibly by inhibiting CaMKIIα and its downstream signaling.
This work was supported in part by a grant (K07 AT003647) from the National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health (NIH http://www.nih.gov). Nanoparticle formation and characterization were supported by NSF Career Award (NSF-CMMI 1350731 http://www.nsf.gov). Mechanistic CaMKII study received funds from NSFc (81328009).
Publisher StatementThis is a copy of an article published in PLoS ONE. © 2016 Public Library of Science Publications. © 2016 Hu et al.
PublisherPublic Library of Science